{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:02:05Z","timestamp":1787785325188,"version":"build-2784847793"},"reference-count":41,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Active illicit drug use can present a barrier to the medical management of HIV infection by complicating adherence to antiretroviral therapy (ART). Plasma HIV-1 RNA viral load (VL) rebound, defined as a period of detectable HIV VL following ART and VL suppression, can lead to the generation of viral resistance and potential treatment failure. We sought to investigate the contribution of substance use patterns on rates of VL rebound.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from the ACCESS study, a long-running community-recruited prospective cohort of HIV-positive people who use illicit drugs in Vancouver, Canada, a setting of universal no-cost HIV treatment. We analysed time to VL rebound (that is, two consecutive observations \u22651,000 copies\/ml) after ART initiation and sustained viral suppression (that is, two consecutive observations &lt;50 copies\/ml) using extended Cox regression models with a recurrent events framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between May 1996 and November 2013, 564 ART-exposed participants achieved at least one instance of VL suppression and contributed 1,893.8 person-years of observation. Over follow-up, 198 (35.1%) participants experienced \u2265 one instance of VL rebound. In adjusted analyses, VL rebound was associated with younger age (adjusted hazard ratio [AHR] =0.97, 95% CI: 0.95, 0.98), heroin injection (\u2265 daily versus &lt; daily, AHR =1.52, 95% CI: 1.01, 2.30), crack use (\u2265 daily versus &lt; daily, AHR = 1.73, 95% CI: 1.08, 1.92) and heavy alcohol use (\u2265 four versus &lt; four drinks\/day, AHR =1.97, 95% CI: 1.17, 3.31).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study suggests that in addition to heavy alcohol use, high-intensity illicit drug use, particularly \u2265 daily heroin injection and \u2265 daily crack smoking are risk factors for VL rebound. In addition to the impact of high-intensity drug use on health-care engagement and ART adherence, some evidence exists on the direct impact of psychoactive substances on ART metabolism and the natural progression of HIV disease. At-risk individuals should be provided additional supports to preserve virological control and maintain the benefits of ART.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3265","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T10:44:19Z","timestamp":1537353859000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":37,"title":["Substance use Patterns and HIV-1 RNA Viral Load Rebound among HIV-Positive Illicit Drug users in a Canadian Setting"],"prefix":"10.1177","volume":"24","author":[{"given":"Farah","family":"Ladak","sequence":"first","affiliation":[{"name":"Department of General Surgery, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Socias","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV\/AIDS, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonaid","family":"Nolan","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV\/AIDS, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiru","family":"Dong","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV\/AIDS, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV\/AIDS, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV\/AIDS, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Montaner","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV\/AIDS, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-J","family":"Milloy","sequence":"additional","affiliation":[{"name":"Department of General Surgery, University of Alberta, Edmonton, AB, Canada"},{"name":"British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV\/AIDS, St. Paul's Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,1,1]]},"reference":[{"key":"bibr1-IMP3265","unstructured":"UNAIDS. Gap Report. 2014. (Accessed 4 December 2018.) Available from http:\/\/www.unaids.org\/en\/resources\/campaigns\/2014\/2014gapreport\/gapreport"},{"key":"bibr2-IMP3265","author":"Cook C.","year":"2016","journal-title":"Harm Reduction International"},{"key":"bibr3-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.002"},{"key":"bibr4-IMP3265","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000243"},{"key":"bibr5-IMP3265","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2009.184796"},{"key":"bibr6-IMP3265","unstructured":"UNODC. World Drug Report. 2016. (Accessed 4 December 2018.) Available from http:\/\/www.unodc.org\/wdr2016\/"},{"key":"bibr7-IMP3265","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01509.x"},{"key":"bibr8-IMP3265","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0913-0"},{"key":"bibr9-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60832-X"},{"key":"bibr10-IMP3265","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182433288"},{"key":"bibr11-IMP3265","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-016-0108-9"},{"key":"bibr12-IMP3265","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1926-z"},{"key":"bibr13-IMP3265","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.6.547"},{"key":"bibr14-IMP3265","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.10.1175-b"},{"key":"bibr15-IMP3265","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.5.550"},{"key":"bibr16-IMP3265","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-22"},{"key":"bibr17-IMP3265","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181900129"},{"key":"bibr18-IMP3265","first-page":"293","volume":"85","author":"Siddiqui N.S.","year":"1993","journal-title":"J Natl Med Assoc"},{"key":"bibr19-IMP3265","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830507f2"},{"key":"bibr20-IMP3265","doi-asserted-by":"publisher","DOI":"10.2741\/2162"},{"key":"bibr21-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(97)00229-4"},{"key":"bibr22-IMP3265","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-006-9023-5"},{"key":"bibr23-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.01.001"},{"key":"bibr24-IMP3265","doi-asserted-by":"publisher","DOI":"10.1086\/433175"},{"key":"bibr25-IMP3265","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199009000-00006"},{"key":"bibr26-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2009.05.007"},{"key":"bibr27-IMP3265","doi-asserted-by":"publisher","DOI":"10.1203\/01.PDR.0000074973.83826.4C"},{"key":"bibr28-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(97)00224-5"},{"key":"bibr29-IMP3265","doi-asserted-by":"publisher","DOI":"10.2741\/1651"},{"key":"bibr30-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2003.10.011"},{"key":"bibr31-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09411-4"},{"key":"bibr32-IMP3265","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.20.11425-11428.2004"},{"key":"bibr33-IMP3265","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj059"},{"key":"bibr34-IMP3265","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000127354.78706.5d"},{"key":"bibr35-IMP3265","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181b18b6e"},{"key":"bibr36-IMP3265","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2004.00244.x"},{"key":"bibr37-IMP3265","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318067b4fd"},{"key":"bibr38-IMP3265","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2000.tb04646.x"},{"key":"bibr39-IMP3265","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2009.0211"},{"key":"bibr40-IMP3265","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)63099-6"},{"key":"bibr41-IMP3265","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-010-0060-6"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3265","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3851\/IMP3265","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:38Z","timestamp":1777380758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.3851\/IMP3265"],"URL":"https:\/\/doi.org\/10.3851\/imp3265","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}